Major Research and Innovation Application Support
Round 4 – Targeted Call
CUREator+

Guidelines and Conditions

Applications due by:
1:00 pm (AWST) Tuesday 8 April 2025



Contents

1. Introduction

The Major Research and Innovation Application Support (MRIAS; the Program) is a funding program of the Western Australian (WA) Future Health Research and Innovation (FHRI) Fund.

The FHRI Fund provides a secure source of funding to drive health and medical research, innovation and commercialisation, and through these activities improve the health and prosperity of all Western Australians. It also provides an opportunity to diversify the economy, create jobs, improve the sustainability of the health system and position WA as a leader in research and innovation.

The Program contributes to the FHRI Fund Priority Goal:

- provide cash commitments for submission to major competitive co-funding programs, making Western Australian-led applications more competitive and, therefore, increasing the State's share of national and international competitive funding.

The expected outcomes are in alignment with the following objectives of the *Western Australian Future Health Research and Innovation Fund Act 2012*:

- improving the health and wellbeing of Western Australians
- improving Western Australia's economic prosperity
- advancing Western Australia to being, or maintaining Western Australia's position as, a national or international leader in research and innovation activities.

The Program is administered by the Office of Medical Research and Innovation (OMRI), WA Department of Health (the Department). Queries may be directed to DOH.OMRI@health.wa.gov.au.

2. Purpose

The purpose of MRIAS is to provide a competitive mechanism to allocate State Government co-funding support to competitive research and innovation applications to national or international grant funding programs.

The aims of the Program are to:

- promote high-quality research and innovation in WA
- enable opportunities for the translation or commercialisation of research or innovation outcomes to improve the health and/or wellbeing of the WA community
- enhance WA's standing as a leader in health and medical research and innovation.

The objectives of the Program are to:

- improve WA success rates for eligible health and medical research and innovation grant funding programs (External Programs)
- increase the competitive grant income brought into, and expended in, WA.

3. Program description

The Program provides in-principle cash commitments for WA research or innovation applications being submitted to nationally or internationally competitive external grant funding programs (External Programs), that either require State Government co-funding, or encourage applications that include co-funding.

MRIAS supports applications for research or innovation co-funding that:

- build WA capability and capacity in research or innovation
- address significant health and medical issues in WA

- attract additional competitive grant funding that is expended in WA.

For this round, only shortlisted applicants of the Brandon Catalyst and ANDHealth CUREator+ program (CUREator+), which is funded by the Medical Research Future Fund 2024 BioMedTech Incubator grant opportunity, will be accepted.

Applications to CUREator+ that address the FHRI Fund Focus Areas of Aboriginal, rural and regional health, Burden of diseases, Living with COVID-19 and Long-COVID or Mental Health are encouraged.

The Activity Lead is responsible for ensuring all partners in the proposed Activity are adequately involved in the development of the CUREator+ application.

The Activity Lead must provide OMRI with a copy of their CUREator+ application prior to submission. If unsuccessful, the Activity Lead must provide a copy of feedback received to OMRI.

Commitments of in-principle cash support will be made through a competitive and merit-based process.

The Activity Lead must advise OMRI as soon as they are notified of the outcome of their application to CUREator+.

The Activity Lead will be responsible for coordinating the Activity and complying with all reporting requirements, if successful.

The Responsible Entity* will be accountable for the governance and financial management of any funding awarded.

* *It is acknowledged that the term Administering Institution has traditionally been used by universities and research institutes, however the term Responsible Entity is inclusive of industry and reflects that grant agreements are the responsibility of the contracted entity*.

4. Eligibility

To be eligible for this Program all of the following criteria apply:

- The Responsible Entity must:
  - have an active Australian Business Number (ABN)
  - have a physical and operational presence in WA
  - be an organisation who is an eligible administering, leading, or co-leading organisation on the CUREator+ application.
- The Activity Lead must:
  - be an Australian or New Zealand citizen, a permanent resident of Australia, or have an appropriate work visa in place for the duration of the Activity
  - physically reside in WA for a minimum of 80 per cent of the period of the Activity
  - have no overdue reports for any grant funding program administered by OMRI (including FHRI Fund programs) from any year (excludes authorised extensions)
  - ensure that funding has not been awarded for any component of the Activity
  - have a position or title at the Responsible Entity for the period of the Activity.
    The Activity Lead will be required to declare which of the following applies:
    (a) employee of the Responsible Entity; or
    (b) honorary or adjunct title at the Responsible Entity.
    In the case of (a), if the Activity Lead is also employed by the WA public health system (may include Clinical Academics) they will register (WA Health staff access only) a Conflict of Interest for this grant in accordance with the Department of

Health Managing Conflicts of Interest Policy that addresses how the Activity Lead intends to ensure WA Health intellectual property (IP) is protected.
In the case of (b), if the Activity Lead is employed by another entity (the Employer), this entity must have an active ABN, a physical and operational presence in WA and evidence must be provided that either:

i. *an affiliation agreement* exists between the Responsible Entity and the relevant Employer; or*
ii. *the intention is for this Activity to be subcontracted* to the relevant Employer and there is in-principle agreement between the Responsible Entity and the Employer for this arrangement.*

** the affiliation/subcontract agreement must clearly define each entity's responsibilities in relation to the Activity, and in accordance with the 'Contractual arrangements' section below, include relevant permissions to use third-party intellectual property (IP) required to deliver the Activity and address ownership of new IP generated by the Activity.*

- Any rights (for example Intellectual Property rights) to develop or implement an innovation must be vested with the innovation Activity team, or otherwise not be vested in another entity in a manner which would preclude the ability of the Activity team to deliver the innovation (Freedom to Operate).
- The Responsible Entity or other entities that fund or are involved in the Activity must not be part of an industry that produces products or services that may contribute to poor physical health or mental wellbeing of the community.
- The grant funding must not constitute the entire financial base of the Responsible Entity i.e. the Responsible Entity must have other external sources of income.
- The Responsible Entity must ensure applications meet all eligibility criteria set out in these guidelines and in the CUREator+ guidelines.
- Applications must be submitted in accordance with the 'Application instructions' section of this document.
- An application may be deemed ineligible and excluded from further consideration if OMRI identifies that:
    - the application is not shortlisted for CUREator+
    - it does not meet all eligibility criteria as set out in these or the CUREator+ guidelines
    - the proposed Activity duplicates activity previously or currently being undertaken
    - it is not undertaking an innovation or research activity e.g. is a 'business as usual activity', such as quality improvement
    - it includes any incomplete, false or misleading information
    - it was submitted after the advertised closing date and time.
- Grant offers may be withdrawn if it is determined that eligibility criteria are not met.
- OMRI reserves the right to request further information and make final decisions regarding eligibility.
- Decisions made in relation to previous grant programs will not be regarded as precedents and will not be considered when assessing eligibility for this grant program.

5. Program funding

The cash amount requested in the MRIAS application can be up to $1 million (excluding GST) per application, paid over a period of up to 6 years.

The requested amount cannot exceed the total amount of the cash requested from CUREator+ and other partner cash contributions (combined). In-kind contributions are excluded from this amount.

The amount requested from the FHRI Fund through the Program, partners and CUREator+ must allow for expenditure in WA to be at least double the MRIAS funding amount requested.

Funding will not be disbursed until evidence is provided to OMRI that the CUREator+ application has been successful, and an appropriate funding agreement for CUREator+ has been executed.

Requested FTE, salary level, costs and duration must reasonably reflect the proposed Activity and be directly attributable to the delivery of the proposed Activity.

Funding will be in accordance with the following:

- Salary costs:
    - may include Award/Agreement increases and salary increments as appropriate
    - may include leave entitlements that accrue and are taken during the period the salary is being paid by the grant funding (noting annual leave is accrued at a rate of 7.69% and long service leave at a rate of 2.5% of the base salary paid by grant funding)
    - may not include leave entitlements accrued outside this period, parental leave, sabbatical, severance and termination payments
    - may include superannuation, payroll tax and workers compensation as on-costs up to a maximum of 30%, noting that WA public health system salaries can only include superannuation as a salary on-cost
    - are not to provide salary for the Activity Lead. An exemption to this rule may be requested, where it is deemed that this salary is crucial to the success of the Activity. Adequate justification must be provided. Determination of exemptions will be made on a case-by-case basis, at the discretion of OMRI.
- Non-salary costs:
    - may include expenses such as essential services, supplies, unique equipment and consumer involvement
    - for travel will not be approved unless strongly justified as being essential to the undertaking of the Activity and must not include costs related to conference attendance
    - may be requested for equipment, however, the total value of all equipment items must not exceed 10% of the budget request or $15,000, whichever is the lesser amount, and quotes for each item must be attached to the application.
- Overhead charges:
    - may be requested up to a maximum of 10% of the total budget, noting that WA public health system Responsible Entities cannot claim overhead charges in accordance with the Financial Management Manual s522 (grant funding administered by OMRI is exempt).

Funding will only be made available for the scope of work* described in the Application Form, or any modifications to the scope of work approved in writing by OMRI. The

Department will not underwrite any costs beyond the funding awarded through the Program.

The intention is that funding will be spent within WA unless goods and services expenditure items are not available in WA and/or it is beneficial to WA if goods or services are procured from outside WA.

All budget items must be adequately described and justified as consideration is given to budgets during the assessment process.

Budgets must be calculated accurately, as requests for additional funding will not be considered.

In-principle support and subsequent funding is offered subject to budget availability, which could be varied in the event of unforeseen circumstances.

Letter of commitment

Successful applicants to the MRIAS program will be provided with a letter outlining the in-principle cash commitment and a Letter of Support to accompany their application to CUREator+.

If the Letter of Support is required to be provided on a specific format or template by CUREator+ the Activity Lead must indicate this on the Application Form and provide the template to OMRI, upon notification of their successful application.

If CUREator+ does not mandate a specific format or template, the Activity Lead should provide guidance to OMRI regarding the information to be included in the letter, preferably in a template with standardised wording.

6. Application instructions

The instructions below must be followed when making a submission:

- The Application Form must be submitted via email to DOH.OMRI@health.wa.gov.au by **1:00 pm (AWST) Tuesday 8 April 2025**.
- Applicants must include a copy of the CUREator+ guidelines.
- Applications must be complete, include requested certifications and be submitted by the closing date/time. Consideration must be given to the time needed to comply with internal deadlines.
- The file should be named ‘MRIAS2024-25R4-TargetedCall’.

Acknowledgement of receipt of the application will be provided via email to the Activity Lead after submission.

Queries related to the Guidelines and Conditions can be directed to DOH.OMRI@health.wa.gov.au with the subject line beginning with ‘Query – MRIAS2024-25R4-TargetedCall’.

7. Selection process

Assessment process

Commitments of in-principle support will be made through a competitive, merit-based process, and will only be made for high-quality proposals.

All eligible applications will be referred for assessment and scoring by a review panel comprising of experienced researchers and innovators, subject matter experts and consumer representative(s).

Conflicts of interest that may arise will be treated in accordance with the WA health system Managing Conflicts of Interest Policy.

The assessment will be based on the criteria and % weightings set out in the table below and will include an assessment of the MRIAS application against the CUREator+ assessment criteria.

It is expected that applicants will use the MRIAS review panel's feedback to further develop their CUREator+ application prior to submission.

Assessment Criteria	%
Competitiveness for CUREator+ funding • The MRIAS applications competitiveness against the CUREator+ assessment criteria.	**40**
Significance of the Activity for WA • The significance of the issue or opportunity for WA (relevance/scale). • How the proposed Activity will address the issue or opportunity. • Potential to build WA capability and capacity in research and/or innovation. • The expected benefits to the WA community (e.g. reduced inequities, improved health outcomes, economic, social and environmental benefits). • Potential for translation and implementation of findings into policy, practice and/or the development of new processes, products and/or services, and commercialisation, if applicable.	**40**

Alignment with FHRI Fund Focus Areas
• The primary purpose of the application addresses the FHRI Fund Focus Areas:
  ○ Aboriginal, rural and regional health
  ○ Burden of diseases
  ○ Living with COVID-19 and Long COVID
  ○ Mental health.
	10

Consumer involvement • How consumers (people with a lived experience of a health issue, including patients, carers and people who use health care services) have been involved in the development of the proposed Activity. • Plan for ongoing engagement in the Activity, including their roles and how their lived experience perspectives will inform the Activity through formal and informal processes. Refer to the 'Consumer involvement' section in this document.	**10**

Selection of recipients

Based on the assessment and recommendations of the review panel, the Department will approve the awarding of in-principle co-funding.

Subject to the CUREator+ application being successful, grants will be provided in accordance with the Department's financial and procurement processes and delegation authorities.

OMRI reserves the right to offer lower funding rates than requested and/or request modification to the Activity on a case-by-case basis.

8. Consumer involvement

In line with the National Health and Medical Research Council (NHMRC) definition, consumers are people who have lived experience of a health issue. They include patients and potential patients, carers, and people who use health care services. Consumers can also be people who represent the views and interests of a consumer organisation, a community, or a wider constituency.

There is increasing recognition of the benefits of involving consumers in research and innovation. Effective consumer involvement can ensure research and innovation is relevant to the WA community and improves translation into policy and practice.

Health consumers should be engaged during the development of funding applications and embedded in the proposed Activity by being provided with a detailed description of their role and contribution and, where appropriate, included as a team member.

Consumer involvement should incorporate:

- clearly defined relationships with health consumers or community groups who have 'lived experience' of the issue the Activity addresses
- demonstrated understanding of the benefits derived from involving people with a lived experience
- inclusion of consumers in the Activity where appropriate
- plans to involve consumers in the Activity throughout the delivery timeline
- budget strategy with funds allocated to support, implement and acknowledge consumer involvement (e.g. training opportunities, honoraria and payments, additional time to support involvement activities, administration support and consultations and events associated with involvement activities).

Guidance on consumer involvement can be found at the Consumer and Community Involvement Program website and the NHMRC Statement on Consumer and Community Involvement in Health and Medical Research 2016.

It is recommended that all team members complete the free online 30-minute Consumer and Community Involvement in Health Research course (or equivalent) and for the Activity Lead to complete the free online 30-minute Consumer & Community Involvement and Grant Writing course.

9. Contractual arrangements

Grants are offered in accordance with the Department of Health Grant Funding Agreement (and its Terms and Conditions) which is a legal agreement between the Department of Health (Us) and the Responsible Entity (You).

The Responsible Entity must ensure that appropriate agreements are in place with the Activity Lead, team members and participating entities.

The Department reserves the right to withdraw an offer of award to a Responsible Entity if the Grant Funding Agreement and/or Grant Funding Agreement Terms and Conditions cannot be agreed between the parties.

Insurance

A Responsible Entity external to the WA public health system will be required to provide evidence of insurance as a condition of the Grant Funding Agreement, which may include:

- Public Liability (mandatory for all grants)

- Professional Indemnity (mandatory if the Responsible Entity is conducting a clinical trial, provides any form of medical treatment or advice, training, or will provide any tailored design, advice or specification services)
- Property for the Responsible Entity's replacement value of assets (mandatory for building, plant, machinery, equipment)
- Workers Compensation (mandatory if the Responsible Entity has employees or is paying salaries, noting this includes payments to working Directors)
- Product Liability (mandatory if the Responsible Entity manufactures, supplies, sells, services or repairs a product)
- Motor Vehicle if the Responsible Entity owns vehicles
- Clinical Trials if the Responsible Entity undertakes clinical trials (note this insurance may include Professional Indemnity)
- Cyber Liability if the Activity involves confidential data, e.g. identifiable patient information.

OMRI recommends that you seek advice from your insurance advisors to confirm what level and type of insurance is required for the Activity.

The Responsible Entity is responsible for ensuring participating entities have appropriate insurance.

Note that any Activity that requires site governance approval will also be required to provide evidence of appropriate insurance during the governance process, which may vary depending on the site.

Intellectual Property

Intellectual Property (IP) that arises out of the Activity will vest with the Responsible Entity (You). However, consideration will be given to the provisions of the *Western Australian Government Intellectual Property Policy 2023* (or any future iterations of this), and that IP rights should be allocated to optimise the economic, social or environmental benefits for WA from the use, commercialisation and disposal of the IP. For information, the IP clause that will apply to this Program is:

1. The ownership of any Intellectual Property generated by undertaking the Activity shall vest in You.
2. The ownership of any background or pre-existing Intellectual Property and associated Moral Rights, used or incorporated in the Activity that is presently vested in a Party shall remain vested in that Party, unless otherwise agreed.
3. Each Party will be entirely and solely responsible for the use in the Activity of any Intellectual Property and associated Moral Rights it has provided to undertake the Activity which belongs to, or is licensed from, any other party, and indemnifies the other Party against all claims by a third party arising out of use of that Intellectual Property and associated Moral Rights.
4. Subject to the confidentiality provisions of the Agreement, You hereby grant to Us, a non-exclusive, irrevocable, perpetual, royalty-free licence to use (excluding the ability to sub-licence or grant further licences) any of the Intellectual Property generated in the Activity, and which falls within the scope of WA Health's normal activities. This includes, but is not necessarily limited to, activities related to healthcare provision, teaching, training and research. This license does not automatically extend to any potential or eventual commercial development of the Intellectual Property, and any commercial products that might directly or indirectly result from the Activity Intellectual Property. However, where You believe that there is the potential for commercialisation of the Intellectual Property developed in the

course of the Activity, both Parties shall negotiate in good faith the appropriate legal and beneficial interests, rights and access to the Intellectual Property by Us.

5. You indemnify and will keep indemnified Us and all Our respective officers, employees and agents from and against all costs, losses, expenses, actions, suits, demands, claims, damages and other liabilities resulting from Your failure to comply with this agreement, or otherwise resulting from the actual or alleged infringement of the Intellectual Property rights or associated Moral Rights of any third party by You.
6. Your obligations under this Agreement are continuing and survive expiration or termination of the Agreement.

Where relevant, agreements between the Activity Lead, team members and participating entities must include relevant permissions to use third-party IP required to deliver the Activity and have Freedom to Operate for the Activity. When a team includes a member(s) from the WA public health system as a participant in the Activity (i.e. the WA public health entity is not the Responsible Entity), the IP agreement must be authorised at an appropriate level by the relevant WA public health system entity.

Any questions regarding such IP matters should, in the first instance, be directed to OMRI (DOH.OMRI@health.wa.gov.au).

Requests for variation

Requests for variations to the Grant Funding Agreement, such as Activity description, Activity Lead or Responsible Entity, must be directed to OMRI. Approval of the variation will be at the discretion of the Department. If variations are not approved this could result in termination of the grant with associated funding reverting to, or being recoverable by, the Department, where for example eligibility or viability of the Activity is affected.

10. Funding conditions

Payment instalments

Funding will be provided in instalments* to the Responsible Entity as follows:

- The first instalment will be subject to execution of a Grant Funding Agreement
- Subsequent instalments, if applicable, will be subject to provision of satisfactory Progress Reports and will accommodate the funding requirements of the CUREator+ program.

* *Within the WA public health system, payment will be made to the Responsible Entity via a General Ledger Journal (GLJ) transfer progressively upon receipt of evidence of expenditure.*

If ethics and governance approvals are required (refer to ‘Approvals’ section of this document), then the Responsible Entity may only release the first instalment to the Activity Lead once all approvals for the Activity have been obtained and lodged with the Responsible Entity.

Partial payment or suspension of funds

The Department reserves the right to:

- provide funding instalments in parts, based on Activity to date and risk assessment of future Activity
- suspend payment of funding instalments or part instalments where Activity viability has become uncertain.

Additional funding sources

Additional sources of funding are permitted, and encouraged, provided the additional funding supports activities that complement, but do not duplicate, the Activity for which grant funding under this Program is awarded.

Termination of funds

Funds shall revert to, or be recoverable by, the Department in instances where:

- eligibility requirements are no longer met
- the CUREator+ program grant is terminated
- the Activity is terminated by OMRI as a result of insufficient progress being made, or it has been otherwise determined by either the Responsible Entity or OMRI that the Activity is no longer viable
- funds are used for purposes other than those for which they were awarded
- funds were spent on activities that require ethics and/or governance approvals and such approvals were not obtained before undertaking the activities
- funds are not fully expended at the conclusion of the Activity (including any extensions approved by OMRI)
- it is determined that misleading or fraudulent information has been provided
- the Responsible Entity does not enter into formal agreements with respect to this Activity, which includes Intellectual Property ownership, where appropriate
- other entities fund or are involved in the Activity that are part of an industry that produces products or services that may contribute to poor physical health or mental wellbeing of the community.

11. Approvals

Research ethics and research governance

The Responsible Entity, and any participating entity, will be responsible for obtaining and lodging all relevant research ethics and governance approvals that are required for undertaking funded activities, and ensuring these are maintained as required for the duration of the Activity.

Research ethics approvals must be obtained from relevant ethics committees (human and/or animal). Research governance authorisation (also known as site specific assessment or access request review) must be obtained from each relevant institution/site conducting the Activity or providing access to data, participants or tissue samples.

For information on research ethics and governance submission requirements for the WA public health system please refer to the following websites: Research Ethics; Research Governance; Multi-centre Research.

Use of data collections

An Activity that requires access to and use of WA Department of Health data collections requires review and approval for data release in accordance with the *Health Services Act 2016* and the *Health Services (Information) Regulations 2017*. This is in addition to research ethics and governance approvals and will include a feasibility assessment to determine whether the data requested is appropriate for the purposes of the study and approval for use of the data from the data custodian.

Preliminary cost and time estimates can be obtained by contacting DataServ@health.wa.gov.au. Cost estimates should be included in the proposed budget

and an estimate of time for release of the data should be incorporated into the milestones in the Application Form.

For further information please review the Data Linkage Services website.

Should the application for funding be successful, we recommend you immediately begin the data request and approval process.

12. Reporting

The Activity Lead and Responsible Entity are responsible for meeting reporting requirements over the duration of the Activity and at its conclusion.

A copy of all reports provided to the CUREator+ program, either as a requirement of the CUREator+ program or for any other reason, must be forwarded to OMRI within one month of submission.

Progress Activity Report

Progress Reports may be required as stipulated in the Grant Funding Agreement

OMRI reserves the right to request a Progress Report at any point.

OMRI reserves the right to suspend or withdraw funding where insufficient progress has been made.

Final Activity Report

A Final Report detailing the Activity and outcomes must be submitted to OMRI at the conclusion of the Activity. Failure to submit the Final Report at this time may render the Activity Lead ineligible for further funding from the FHRI Fund and OMRI until the Final Report is received.

Financial Report

A financial acquittal statement outlining the expenditure of funds must be submitted to OMRI at the conclusion of the Activity. Acquittal statements must be certified by an authorised finance officer (or equivalent) of the Responsible Entity.

OMRI reserves the right to request interim Financial Reports at any stage during the Activity.

Any unexpended funds must be returned to the Department. Any over-expenditure is the responsibility of the Responsible Entity, and no claim may be made against the Department.

Community Stakeholder Brief

In order to provide feedback to consumers, a one-page *Community Stakeholder Brief* which includes an outline of the Activity, its outcomes, and next steps is to be provided to all participating consumers and a copy submitted to OMRI with the Final Activity Report.

13. Publicising, acknowledgements and publications

All details and information regarding MRIAS applications will be kept confidential until outcomes of the CUREator+ program application have been announced.

Acknowledging there is an embargo period for successful CUREator+ program applicants, MRIAS applicants must contact the OMRI as soon as they are advised by the CUREator+ program that they have been successful.

The Department will work with the Responsible Entity to determine announcement dates, noting that the CUREator+ program publicity conditions, if any, take precedence

The Minister for Medical Research and/or the Department will publicly announce recipients, including the title of the Activity. All other parties must withhold announcement/media coverage until after OMRI advises this has occurred.

Acknowledgement of FHRI Fund support must be made in publications, conference presentations, public discussion, press statements etc. A copy of any published material or media must be provided to Us.

In order to maximise knowledge exchange, funding recipients must comply with the NHMRC 'Publication and dissemination of research: a guide supporting the Australian Code for the Responsible Conduct of Research', which can be downloaded from the Australian Code for the Responsible Conduct of Research page, and the NHMRC Open Access Policy.

14. Confidentiality

Activity title, Activity Lead, funding amount, Responsible Entity, plain language summaries and sections indicated on applications or reports may be used for publicity purposes.

All other information provided in applications and reports will be maintained confidentially by OMRI, review panels, evaluation panels and the FHRI Fund Advisory Council. If requests are received by OMRI to make public any aspect of the Activity, other than the aspects listed above, the authorisation of the Responsible Entity will be sought, notwithstanding information requested under the *Freedom of Information Act 1992 (WA)* or information pertaining to the receipt of State Government financial assistance tabled in the Parliament of Western Australia.

15. Evaluation

OMRI undertakes evaluations of Funding Programs, which will include unsuccessful applications. All parties in the application, including team members and consumer representatives, are required to contribute to the evaluation.

16. Complaints

Responsible Entities or Activity Leads who feel that their interests have been adversely affected by an action taken by OMRI in administering the Program may lodge a complaint. Complaints can only be considered when they refer to the administrative process and not to the funding decision. Complaints must be submitted via email (marked Confidential) to: Deputy Director General (OfficeoftheDDG@health.wa.gov.au).

This document can be made available in alternative formats on request for a person with a disability.

© Department of Health 2025

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism, or review, as permitted under the provisions of the *Copyright Act 1968*, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.